Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11636168 | 1.00 | KMT2A (0.66) | KMT2AADORA2AADORA1ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL11638858 | 0.98 | KMT2A (0.64) | KMT2AADORA2AADORA1ALDH1A1KDM4E | |
| SCHEMBL20929742 | 0.81 | NR3C2 (0.46) | KMT2APIK3CAMTORMAP3K12PRKDC | |
| SCHEMBL11636266 | 0.81 | NR3C2 (0.46) | KMT2APIK3CAMTORMAP3K12PRKDC | |
| SCHEMBL24156925 | 0.81 | KMT2A (0.68) | KMT2AADORA2AADORA1ALDH1A1KDM4E | |
| SCHEMBL19012466 | 0.81 | KMT2A (0.68) | KMT2AADORA2AADORA1ALDH1A1KDM4E | |
| SCHEMBL20929369 | 0.79 | KMT2A (1.00) | KMT2AALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL20929375 | 0.79 | KMT2A (1.00) | KMT2AALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL21588370 | 0.79 | KMT2A (1.00) | KMT2AALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL20929744 | 0.79 | KMT2A (0.41) | KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4265254-A2 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-05 | — | — | US | disclosed |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-05 | — | — | US | disclosed |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-05 | — | — | US | disclosed |
| EP-3697784-B1 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-04 | — | — | EP | disclosed |
| US-11564923-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2023-01-31 | — | — | US | disclosed |
| US-11564923-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2023-01-31 | — | — | US | disclosed |
| US-20210169879-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210169879-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2019076716-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169879-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL15, IL2, IL23R | KMT2A 3992/4885ADORA2A 831/4885ADORA1 516/4885 |
| US-11564923-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL15, IL2, IL33 | KMT2A 3843/4885ADORA2A 913/4885ADORA1 526/4885 |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL15, IL2, IL33 | KMT2A 3843/4885ADORA2A 913/4885ADORA1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.